HIV Infections Clinical Trial
Official title:
A Randomized Controlled Pilot Study to Examine the Impact of a Filmed Dramatized Story Intervention (Telenovela/Soap Opera) for HIV Prevention in Latinas.
Latinas continue to be affected disproportionally by HIV in the United States (US). Often, Latinas are not aware of their HIV status. Also, their perception of low risk for HIV interferes with condom use, HIV testing and lack of awareness, access, and use of Pre-exposure Prophylaxis [PrEP]. About 60% of total HIV cases in NC occur among women of childbearing age, thus vulnerability to HIV is particularly acute among Latinas between ages 18 and 44 years old, an age group with the highest rate of new HIV infections in NC. These disparities indicate that HIV prevention among Latinas is urgent; therefore, the investigators propose an innovative intervention - a filmed dramatized story (telenovela/soap opera) Infección de Amor [IA] (Love Infection) - culturally tailored for Latinas in the US and delivered online. Infección de Amor was filmed and developed but has not been tested with the target audience. The proposed study will pilot test IA and move the intervention to online using a website that will allow individual access around the clock from any location and device, such as a smartphone, ensuring wide dissemination of the intervention in the future. This is a a two-year planning grant (R34) to prepare for an R01 efficacy trial. The aims are to: 1) Develop the intervention delivery website, conduct a website usability test, and test the feasibility and acceptability of the IA intervention (four telenovela episodes) with 10 Latinas, 2) Conduct a randomized controlled pilot study to examine change in HIV prevention behaviors (condom use; HIV testing; and PrEP awareness, access, and use) comparing 71 intervention and 71 control Latinas from baseline (Time 1 [T1], 0 months) to post-active intervention (Time 2 [T2], 1 month), and to six months follow-up, a period with no contact from the study staff (Time 3 [T3, 7 months]), and 3) Complete establishing the study infrastructure, expanding the multidisciplinary team, building the research partnerships with the community, finalize the protocol and training materials, refine recruitment and retention strategies, data collection and data management procedures, and obtain institutional review board approval in preparation for an R01 efficacy study. This study address the National Institute on Drug Abuse (NIDA) goal #4: increase NIDA research and programs' public impact. This is a novel intervention to advance HIV prevention for Latinas. This study implement a culturally durable and feasible intervention for Latinas.
| Status | Recruiting |
| Enrollment | 142 |
| Est. completion date | July 30, 2024 |
| Est. primary completion date | April 30, 2024 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Female |
| Age group | 18 Years to 44 Years |
| Eligibility | Inclusion Criteria: - Self-identified as a Latina - Assigned female gender at birth - Fluent in English or Spanish - Between 18 and 44 years old - Report sexual activity with a man in the last 6 months - Have internet access from any device - Reside in NC Exclusion Criteria: - Unwilling to be part of the study - Do not read, speak, or understand Spanish or English - Do not have access to internet - HIV positive |
| Country | Name | City | State |
|---|---|---|---|
| United States | University of North Carolina at Chapel Hill | Chapel Hill | North Carolina |
| Lead Sponsor | Collaborator |
|---|---|
| University of North Carolina, Chapel Hill | National Institute on Drug Abuse (NIDA) |
United States,
Bauermeister JA, Meanley S, Pingel E, Soler JH, Harper GW. PrEP awareness and perceived barriers among single young men who have sex with men. Curr HIV Res. 2013 Oct;11(7):520-7. doi: 10.2174/1570162x12666140129100411. — View Citation
Blackstock OJ, Patel VV, Felsen U, Park C, Jain S. Pre-exposure prophylaxis prescribing and retention in care among heterosexual women at a community-based comprehensive sexual health clinic. AIDS Care. 2017 Jul;29(7):866-869. doi: 10.1080/09540121.2017.1 — View Citation
Card J, Solomon J, Berman J, eds. Tools for building culturally competent HIV prevention programs. New York: Springer Publishing Company; 2008.
Catania J. Dyadic sexual communication scale: Handbook of sexuality related measures. 1986.
Catania JA, Kegeles SM, Coates TJ. Towards an understanding of risk behavior: an AIDS risk reduction model (ARRM). Health Educ Q. 1990 Spring;17(1):53-72. doi: 10.1177/109019819001700107. — View Citation
Center for Disease Control and Prevention (CDC). HIV among women. https://www.cdc.gov/hiv/group/gender/women/index.html. Updated 2020
Center for Disease Control and Prevention (CDC). Women and HIV: Where we are going. https://www.hiv.gov/blog/cdc-women-and-hiv-where-we-are-going. Updated 2019
Cianelli R, Ferrer L, McElmurry BJ. HIV prevention and low-income Chilean women: machismo, marianismo and HIV misconceptions. Cult Health Sex. 2008 Apr;10(3):297-306. doi: 10.1080/13691050701861439. — View Citation
Cianelli R, Ferrer L, Norr KF, Miner S, Irarrazabal L, Bernales M, Peragallo N, Levy J, Norr JL, McElmurry B. Mano a Mano-Mujer: an effective HIV prevention intervention for Chilean women. Health Care Women Int. 2012;33(4):321-41. doi: 10.1080/07399332.20 — View Citation
Cianelli R, Villegas N. Social Determinants of Health for HIV Among Hispanic Women. Hisp Health Care Int. 2016 Mar;14(1):4-9. doi: 10.1177/1540415316629672. No abstract available. — View Citation
Cianelli R, Villlegas N, De Oliveira G, Hires K, Gattamorta K, Ferrer L, Peragallo N. Predictors of HIV enacted stigma among Chilean women. J Clin Nurs. 2015 Sep;24(17-18):2392-401. doi: 10.1111/jocn.12792. Epub 2015 Feb 19. — View Citation
De Oliveira G, Cianelli R, Gattamorta K, Kowalski N, Peragallo N. Social Determinants of Depression Among Hispanic Women. J Am Psychiatr Nurses Assoc. 2017 Jan/Feb;23(1):28-36. doi: 10.1177/1078390316669230. Epub 2016 Sep 19. — View Citation
Garcia J, Perez-Brumer AG, Cabello R, Clark JL. "And Then Break the Cliche": Understanding and Addressing HIV Vulnerability Through Development of an HIV Prevention Telenovela with Men Who Have Sex with Men and Transwomen in Lima, Peru. Arch Sex Behav. 2018 Oct;47(7):1995-2005. doi: 10.1007/s10508-017-1119-x. Epub 2018 Feb 20. — View Citation
Garcia M, Harris AL. PrEP awareness and decision-making for Latino MSM in San Antonio, Texas. PLoS One. 2017 Sep 27;12(9):e0184014. doi: 10.1371/journal.pone.0184014. eCollection 2017. — View Citation
Geter Fugerson A, Sutton MY, Hubbard McCree D. Social and Structural Determinants of HIV Treatment and Care Among Hispanic Women and Latinas Living with HIV Infection in the United States: A Qualitative Review: 2008-2018. Health Equity. 2019 Nov 4;3(1):58 — View Citation
Heckman T, Kelly J, Sikkema K, et al. HIV risk characteristics of young adult, adult, and older adult women who live in inner-city housing developments: Implications for prevention. J Women's Health Gend Based Med. 1995;4(4):397-406.
Kelly JA, Murphy DA, Washington CD, Wilson TS, Koob JJ, Davis DR, Ledezma G, Davantes B. The effects of HIV/AIDS intervention groups for high-risk women in urban clinics. Am J Public Health. 1994 Dec;84(12):1918-22. doi: 10.2105/ajph.84.12.1918. — View Citation
Larkey LK, Hecht ML, Miller K, Alatorre C. Hispanic cultural norms for health-seeking behaviors in the face of symptoms. Health Educ Behav. 2001 Feb;28(1):65-80. doi: 10.1177/109019810102800107. — View Citation
Lelutiu-Weinberger C, Golub SA. Enhancing PrEP Access for Black and Latino Men Who Have Sex With Men. J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):547-555. doi: 10.1097/QAI.0000000000001140. — View Citation
Levison JH, Bogart LM, Khan IF, Mejia D, Amaro H, Alegria M, Safren S. "Where It Falls Apart": Barriers to Retention in HIV Care in Latino Immigrants and Migrants. AIDS Patient Care STDS. 2017 Sep;31(9):394-405. doi: 10.1089/apc.2017.0084. — View Citation
MedPage Today. PrEP use among heterosexual women. https://www.medpagetoday.com/resource-centers/contemporary-hiv-prevention/prep-use-among-heterosexual-women/1593. Updated 2020.
Miller-Day M, Hecht ML. Narrative means to preventative ends: a narrative engagement framework for designing prevention interventions. Health Commun. 2013;28(7):657-70. doi: 10.1080/10410236.2012.762861. Epub 2013 Aug 27. — View Citation
Nabi RL. Emotional flow in persuasive health messages. Health Commun. 2015;30(2):114-24. doi: 10.1080/10410236.2014.974129. — View Citation
Nabi RL. Laughing in the Face of Fear (of Disease Detection): Using Humor to Promote Cancer Self-Examination Behavior. Health Commun. 2016 Jul;31(7):873-83. doi: 10.1080/10410236.2014.1000479. Epub 2015 Dec 11. — View Citation
National Institute on Minority Health and Health Disparities. National institute on minority health and health disparities research framework. https://nimhd.nih.gov/about/overview/research-framework/nimhd-framework.html. Updated 2018
Paz K, Massey KP. Health Disparity among Latina Women: Comparison with Non-Latina Women. Clin Med Insights Womens Health. 2016 Jul 20;9(Suppl 1):71-4. doi: 10.4137/CMWH.S38488. eCollection 2016. — View Citation
Peragallo Montano N, Cianelli R, Villegas N, Gonzalez-Guarda R, Williams WO, de Tantillo L. Evaluating a Culturally Tailored HIV Risk Reduction Intervention Among Hispanic Women Delivered in a Real-World Setting by Community Agency Personnel. Am J Health — View Citation
Peragallo N, Deforge B, O'Campo P, Lee SM, Kim YJ, Cianelli R, Ferrer L. A randomized clinical trial of an HIV-risk-reduction intervention among low-income Latina women. Nurs Res. 2005 Mar-Apr;54(2):108-18. doi: 10.1097/00006199-200503000-00005. Erratum I — View Citation
Radloff LS. The CES-D scale: A self report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385-401
Sanchez M, Rojas P, Li T, Ravelo G, Cyrus E, Wang W, Kanamori M, Peragallo NP, De La Rosa MR. Evaluating a Culturally Tailored HIV Risk Reduction Intervention Among Latina Immigrants in the Farmworker Community. World Med Health Policy. 2016 Sep;8(3):245-262. doi: 10.1002/wmh3.193. Epub 2016 Sep 17. — View Citation
Sikkema KJ, Heckman TG, Kelly JA, Anderson ES, Winett RA, Solomon LJ, Wagstaff DA, Roffman RA, Perry MJ, Cargill V, Crumble DA, Fuqua RW, Norman AD, Mercer MB. HIV risk behaviors among women living in low-income, inner-city housing developments. Am J Publ — View Citation
Straus MA, Douglas EM. A short form of the Revised Conflict Tactics Scales, and typologies for severity and mutuality. Violence Vict. 2004 Oct;19(5):507-20. doi: 10.1891/vivi.19.5.507.63686. — View Citation
Torrone EA, Wright J, Leone PA, Hightow-Weidman LB. Pregnancy and HIV infection in young women in North Carolina. Public Health Rep. 2010 Jan-Feb;125(1):96-102. doi: 10.1177/003335491012500113. — View Citation
Villar-Loubet OM, Vamos S, Jones DL, Lopez E, Weiss SM. A Cultural Perspective on Sexual Health: HIV Positive and Negative Monolingual Hispanic Women in South Florida. Hisp Health Care Int. 2011 Jun 1;9(2):82-90. doi: 10.1891/1540-4153.9.2.82. — View Citation
Villegas N, Santisteban D, Cianelli R, Ferrer L, Ambrosia T, Peragallo N, Lara L. Pilot testing an internet-based STI and HIV prevention intervention with Chilean women. J Nurs Scholarsh. 2015 Mar;47(2):106-16. doi: 10.1111/jnu.12114. Epub 2014 Nov 19. — View Citation
Villegas N, Santisteban D, Cianelli R, Ferrer L, Ambrosia T, Peragallo N, Lara L. The development, feasibility and acceptability of an Internet-based STI-HIV prevention intervention for young Chilean women. Int Nurs Rev. 2014 Mar;61(1):55-63. doi: 10.1111 — View Citation
Walsh JL. Applying the Information-Motivation-Behavioral Skills Model to Understand PrEP Intentions and Use Among Men Who Have Sex with Men. AIDS Behav. 2019 Jul;23(7):1904-1916. doi: 10.1007/s10461-018-2371-3. — View Citation
Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988 Jun;54(6):1063-70. doi: 10.1037//0022-3514.54.6.1063. — View Citation
Wingood GM, DiClemente RJ, Villamizar K, Er DL, DeVarona M, Taveras J, Painter TM, Lang DL, Hardin JW, Ullah E, Stallworth J, Purcell DW, Jean R. Efficacy of a health educator-delivered HIV prevention intervention for Latina women: a randomized controlled trial. Am J Public Health. 2011 Dec;101(12):2245-52. doi: 10.2105/AJPH.2011.300340. Epub 2011 Oct 20. — View Citation
Zou B, Jin B, Koch GG, Zhou H, Borst SE, Menon S, Shuster JJ. On model selections for repeated measurement data in clinical studies. Stat Med. 2015 May 10;34(10):1621-33. doi: 10.1002/sim.6414. Epub 2015 Jan 23. — View Citation
* Note: There are 40 references in all — Click here to view all references
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change in Condom Use from Baseline to Month 1 | Changes in condom use will be measured as the number of sexual episodes (oral, vaginal, or anal intercourse) in which condoms were used with a male partner in the last month. | baseline up to 1 month | |
| Primary | Change in Condom Use from Baseline to Month 7 | Changes in condom use will be measured as the number of sexual episodes (oral, vaginal, or anal intercourse) in which condoms were used with a male partner in the last month. | baseline up to 7 months | |
| Primary | Changes in Pre-exposure Prophylaxis [PrEP] Awareness from Baseline to Month 1 | Changes in PrEP awareness will be measured as the number of participants who self-report whether they know about PrEP medication (dichotomous question: yes/no) | baseline up to 1 month | |
| Primary | Changes in Pre-exposure Prophylaxis [PrEP] Awareness from Baseline to Month 7 | Changes in PrEP awareness will be measured as the number of participants who self-report whether they know about PrEP medication (dichotomous question: yes/no) | baseline up to 7 months | |
| Primary | Changes in Pre-exposure Prophylaxis [PrEP] Access from Baseline to Month 1 | Changes in PrEP access will be measured as the number of participants who report that they have access to PrEP (dichotomous question: yes/no) | baseline to 1 month | |
| Primary | Changes in Pre-exposure Prophylaxis [PrEP] Access from Baseline to Month 7 | Changes in PrEP access will be measured as the number of participants who report that they have access to PrEP (dichotomous question: yes/no) | baseline to 7 months | |
| Primary | Changes in Pre-exposure Prophylaxis [PrEP] Use from Baseline to Month 1 | Changes in PrEP use will be measured as the number of participants who self-report whether they use PrEP medication (dichotomous question: yes/no) | baseline to 1 month | |
| Primary | Changes in Pre-exposure Prophylaxis [PrEP] Use from Baseline to Month 7 | Changes in PrEP use will be measured as the number of participants who self-report whether they use PrEP medication (dichotomous question: yes/no). | baseline up to 7 months | |
| Primary | Change in HIV Testing from Baseline to Month 1 | Changes in HIV testing will be measured as the number of participants who reported to have been tested for HIV in the last month. | baseline up to 1 month | |
| Primary | Change in HIV Testing from Baseline to Month 7 | Changes in HIV testing will be measured as the number of participants who reported to have been tested for HIV in the last month. | baseline up to 7 months | |
| Primary | Change in HIV Test Perception from Baseline to Month 1 | Changes in HIV testing perception will be measured with the willingness to take an HIV test measure scale. Scores range from 9-45. A higher score represents a higher willingness to take an HIV test. | baseline up to 1 month | |
| Primary | Change in HIV Test Perception from Baseline to Month 7 | Changes in HIV testing perception will be measured with the willingness to take an HIV test measure scale. Scores range from 9-45. A higher score represents a higher willingness to take an HIV test. | baseline up to 7 months | |
| Secondary | Number of Participants who Complete all the Intervention Content | The online website will track the number of participants who complete of all intervention content (40-minute of the telenovela episode) | 40-minute | |
| Secondary | Number of Participants Who are Retained Through all Assessments | The number of participants who completed all assessments divided by the number of enrolled participants | baseline up to 7 months | |
| Secondary | Change in Emotional Response | Changes in emotional Response (ER) will be measured with the International Positive and Negative Affect Schedule Short Form (IPANAS-SF). Scores range from 10-50. Higher scores indicate the tendency to experience a positive and negative mood. | Changes in emotional Response (ER) will be measured with the International Positive and Negative Affect Schedule Short Form (IPANAS-SF). Scores range from 10-50. Higher scores indicate the tendency to experience a positive and negative mood. | |
| Secondary | Change in Narrative Engagement | Changes in narrative engagement (NE) will be measured with the Perception of Narrative Performance Scale, which measures three dimensions of engagement: interest, realism, and identification. Scores range from 9-36. A higher score indicates a higher level of engagement. | week 1 to week 4 | |
| Secondary | Change in Self-Efficacy for Condom Use | Changes in Self-Efficacy for condom use will be measured using the HIV self-efficacy for condom use survey. Scores range from 7-28. A higher score indicates a higher level of self-efficacy for condom use. | week 1 to week 4 | |
| Secondary | Emotional response, narrative engagement, and self efficacy as predictors of condom use | The effects of emotional response (ER), Narrative engagement (NE) and Self-efficacy (SE) on condom use will be estimated. ER, NE and SE will be measured using the scales reported on outcomes 15-17 and condom use will be measured as described in outcome 1. A lineal regression model including group assignment (intervention or control), ER, NE and SE as predictors of condom use will be conducted. The estimated regression coefficients (beta) of each independent variable will be reported. Higher estimated regression coefficients represent higher effects of these variables on condom use. | one month to 7 months post baseline | |
| Secondary | Emotional response, narrative engagement, and self efficacy as predictors of HIV testing | The effects of emotional response (ER), Narrative engagement (NE) and Self-efficacy (SE) on HIV testing will be estimated. ER, NE and SE will be measured using the scales reported on outcomes 15-17 and HIV testing will be measured as described in outcome 9. A logistic regression model will be conducted including group assignment (intervention or control), ER, NE and SE as predictors of HIV testing. The estimated odd ratios of each predictor will be reported. Odds ratio greater than 1 will indicate higher occurrence of HIV testing given exposure to the predictors. | one month to 7 months post baseline | |
| Secondary | Emotional response, narrative engagement, and self efficacy as predictors of PrEP awareness | The effects of emotional response (ER), Narrative engagement (NE) and Self-efficacy (SE) on PrEP awareness will be estimated. ER, NE and SE will be measured using the scales reported on outcomes 15-17 and PrEP awareness will be measured as described in outcome 3. A logistic regression model will be conducted including group assignment (intervention or control), ER, NE and SE as predictors of PrEP awareness. The estimated odd ratios of each predictor will be reported. Odds ratio greater than 1 will indicate higher occurrence of PrEP awareness given exposure to the predictors. | one month to 7 months post baseline | |
| Secondary | Change in Substance Abuse from Baseline to Month 7 | Changes in substance abuse will be measured with the Substance abuse behaviors scale. Scores range from 6-36. A higher score represents a higher use of substances. | baseline up to 7 months | |
| Secondary | Change in Intimate Partner Violence (IPV) | Changes in IPV will be measured using the revised Conflict Tactics Scale to measure women's self-reported IPV in the previous 3 months (e.g., your partner insulted you). Scores range from 24-72 points. A higher score indicates higher levels of IPV. | baseline up to 7 months | |
| Secondary | Change in Depression | Changes in depression will be measured with the Patient Health screening in primary care and other health settings. Scores range from 5-27. A higher score indicates more depressive symptoms. | baseline up to 7 months | |
| Secondary | Substance abuse, intimate partner violence, and depression as predictors of condom use | Substance abuse (SA), intimate partner violence (IPV) and depression measured with the scales described in outcome 21-23 will be tested as predictors of condom use (measured as described outcome 1). A linear regression model will be conducted. The estimated regression coefficients (beta) of each predictor will be reported. Higher coefficients indicate a stronger effect of these variables on condom use. | baseline up to 7 months | |
| Secondary | Substance abuse, intimate partner violence, and depression as predictors of HIV testing | Substance abuse (SA), intimate partner violence (IPV) and depression measured with the scales described in outcome 21-23 will be tested as predictors of HIV testing (measured as described outcome 9). A logistic regression model will be conducted. The estimated odds ratio of each independent variable will be reported. Odds ratio greater than 1 will indicate higher occurrence of HIV testing given exposure to the predictors. | baseline up to 7 months | |
| Secondary | Substance abuse, intimate partner violence, and depression as predictors of PrEP awareness | Substance abuse (SA), intimate partner violence (IPV) and depression measured with the scales described in outcome 21-23 will be tested as predictors of PrEP awareness (measured as described outcome 3). A logistic regression model will be conducted. The estimated odds ratio of each predictor will be reported. Odds ratio greater than 1 will indicate higher occurrence of PrEP awareness given exposure to the predictors. | baseline up to 7 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |